Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia.
eagle製藥公司（納斯達克股票代碼：EGRX）今天宣佈將在2024年5月2日至4日於喬治亞州薩凡納舉行的遠程麻醉醫學協會（SAMBA）2024屆年會上提交正在進行的試驗，以討論靜脈舒血胺硫普利在從出生（足月）到17歲的小兒術後噁心嘔吐（PONV）中的預防作用。
"Evaluating nausea in children remains a challenging and complex process," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "We are therefore pleased to have this opportunity to share the details of our ongoing Phase 2/3 study evaluating amisulpride to prevent postoperative nausea and vomiting in pediatric patients at this year's SAMBA 2024 Annual Meeting. Through this study, we hope to demonstrate the potential benefit of amisulpride therapy in this pediatric patient population, and we look forward to presenting preliminary results from this study in the second half of 2025."
“在兒童中評估噁心仍然存在挑戰和複雜的過程，”eagle製藥醫學事務副總裁Mike Greenberg博士表示，“我們很高興有機會在今年的SAMBA 2024年會上分享正在進行的第2/3期致力於評估舒血胺硫普利適用於小兒術後噁心和嘔吐的研究細節。通過這項研究，我們希望展示舒血胺硫普利治療在這個小兒患者人群中的潛在效益，並期待在2025年下半年公佈此研究的初步結果。”
Details of the presentations are as follows:
演示的詳細信息如下:
| Abstract Title: | Randomized, Double-Blind, Parallel-Group Active-Controlled Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients: Trial in Progress |
| Date: | Thursday, May 2, 2024 |
| Times: | 5:10-6:10pm |
| Presenter: | Dr. Lynn Bichajian |
| 摘要標題： | 靜脈舒血胺硫普利作爲預防小兒術後噁心嘔吐的隨機、雙盲、平行組活動對照第2/3期研究：正在進行的試驗 |
| 日期： | 2024年5月2日（星期四） |
| 時間: | 下午5:10至6:10 |
| 報告人： | Lynn Bichajian博士 |